C07K 2317/74
Inducing cell proliferation
C07K2317/74 (Inducing cell proliferation) appears on 793 US grants and 1,337 published applications in this corpus.
Search patents in C07K- Granted patents
- 793
- Published applications
- 1,337
- Assignees
- 565
- Inventors
- 2,472
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 2 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 6 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 7 | 0 |
| 1997 | 8 | 0 |
| 1998 | 17 | 0 |
| 1999 | 16 | 0 |
| 2000 | 16 | 0 |
| 2001 | 13 | 1 |
| 2002 | 11 | 18 |
| 2003 | 12 | 16 |
| 2004 | 8 | 21 |
| 2005 | 8 | 31 |
| 2006 | 10 | 29 |
| 2007 | 7 | 30 |
| 2008 | 9 | 26 |
| 2009 | 18 | 29 |
| 2010 | 16 | 49 |
| 2011 | 23 | 44 |
| 2012 | 15 | 34 |
| 2013 | 23 | 32 |
| 2014 | 17 | 42 |
| 2015 | 28 | 48 |
| 2016 | 34 | 50 |
| 2017 | 37 | 62 |
| 2018 | 26 | 66 |
| 2019 | 41 | 74 |
| 2020 | 54 | 107 |
| 2021 | 55 | 120 |
| 2022 | 53 | 102 |
| 2023 | 67 | 92 |
| 2024 | 49 | 93 |
| 2025 | 57 | 81 |
| 2026 | 25 | 40 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)25 Aug 2026US 12,714,745 B2Baylor Research Institute
- CD8 binding agents and uses thereof25 Aug 2026US 12,715,920 B2Genentech, Inc.
- Anti-TCR delta variable 1 antibodies11 Aug 2026US 12,703,746 B2Adaptate Biotherapeutics Ltd.
- Fusion constructs and methods of using thereof11 Aug 2026US 12,703,747 B2Precigen, Inc.
- Antibodies4 Aug 2026US 12,698,328 B2GammaDelta Therapeutics Ltd
- Anti-cd79b antibody-drug conjugate, and preparation method therefor and pharmaceutical use thereof27 Aug 2026US 2026/0248946 A1
- Anti-trem1 antibody agents, compositions, and uses thereof20 Aug 2026US 2026/0242465 A1Celsius Therapeutics, Inc.
- Novel immunoconjugates13 Aug 2026US 2026/0232829 A1Cytospire Therapeutics Limited
- Il-10 receptor antibodies and methods of use thereof13 Aug 2026US 2026/0234240 A1
- Anti-lilrb1 and/or anti-lilrb2 antibodies and uses thereof13 Aug 2026US 2026/0234247 A1Laekna Pharmaceutical Ningbo Co., Ltd.
Most cited
By later US patents
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Modified antibody variable domains462US 5,766,886 AXoma Corporation · 1998
- Anti-PD-L1 antibodies, compositions and articles of manufacture459US 8,217,149 B2Genentech, Inc. · 2012